X You are viewing the latest eNews for Pharmacists, our weekly email newsletter sent to thousands of professionals and students.

[Return Home]
[Subscribe for Free]
[Become a Sponsor]



NEWS-Line - eNews

FEATURED SPONSOR:

Alliance For Clinical Trials In Oncology
Manager, Pharmaceutical Affairs

Chicago Illinois

Job Board
Find a Job Near You

Nationwide


SPONSORS:

Sign In / Sign Up

Jobs RSS Feed

Your Weekly eNews from NEWS-Line.

Please "Like" NEWS-Line on Facebook and follow us on Twitter, Pinterest, and Linkedin.  Bookmark www.news-line.com to read all of the latest healthcare news that is posted daily.

Also, the October issue of NEWS-Line is available to read on your computer or electronic device. And remember . . . you can take NEWS-Line everywhere with you! Just save www.NEWS-Line.com to your phone for the latest news, jobs, education and blogs!

 



NEWS:

Migraine Drug Used In ER May Not Be Best Option

A drug commonly used in hospital emergency rooms for people with migraine is substantially less effective than an alternate drug and should not be used as a first choice treatment, according to a study published in the online issue of Neurology®, the medical journal of the American Academy of Neurology.

“People go to US emergency departments 1.2 million times a year with migraine, and the opioid drug hydromorphone is used in 25% of these visits, yet there have been no randomized, high-quality studies on its use for acute migraine,” said study author Benjamin W. Friedman, MD, MS, of Albert Einstein College of Medicine in the Bronx, N.Y.

The study found that the drug prochlorperazine, given along with the drug diphenhydramine to prevent the side effect of restlessness, was superior to hydromorphone. Prochlorperazine is a type of drug called a dopamine antagonist. It blocks the release

Read Full Article



Fighting Opioid Addiction In Primary Care: Study Shows It’s Possible

For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

But a new study suggests the answer could lie much closer to home, in the primary care clinics where they go for basic medical care.

Evidence compiled by a University of Michigan team suggests that primary care physicians and their existing teams of nurses, medical assistants, social workers and pharmacists can indeed provide effective addiction care using anti-opioid medication.

The researchers hope their findings will encourage more general practitioners to start offering medication-assisted therapy or MAT. They’ve published the new systematic review of the peer-reviewed evidence in PLoS One as a way of showing which elements worked for primary care physicians and clinics who did try providing MAT.

A drug to get off drugs

Read Full Article

AANP, AAPA And ASAM Partner To Improve Access To Medication Assisted Therapy

The American Association of Nurse Practitioners (AANP), the American Society of Addiction Medicine (ASAM), and the American Academy of Physician Assistants (AAPA), who collectively represent over 350,000 clinicians, are dedicated to increasing access to and improving the quality of addiction treatment for patients across the country. With the opioid addiction and overdose crisis continuing to significantly impact the country, our organizations have partnered in an efforts to assist clinicians gain access to training and understand the federal and state policies that impact how substance use disorder and addiction treatment is provided to its citizens.

This week, our partnership launched an additional effort to coordinate with licensure boards on disseminating information about the regulatory requirements health care professionals need to be aware of as they treat patients. To date, ove

Read Full Article

New Research Opens The Door To ‘Functional Cure’ For HIV

In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively suppresses production of the virus in chronically infected cells, and prevents viral rebound, even when those infected cells are subjected to vigorous stimulation.

The study, led by TSRI Associate Professor Susana Valente, was published online before print in the journal Cell Reports.

“No other anti-retroviral used in the clinic today is able to completely suppress viral production in infected cells in vivo,” Valente said. “When combining this drug with the standard cocktail of anti-retrovirals used to suppress infection in humanized mouse models of HIV-1 infection, our study found a drastic reduction in virus RNA present—it is really the proof-of-concept f

Read Full Article

More News


LINKS:





UPCOMING EVENTS:

Midyear Clinical Meeting

12/03/2017 - 12/07/2017
ASHP


Would you like to be Featured
in NEWS-Line for
Pharmacists?

Click Here